Revolutionizing Medicine: The Power of Thinking Small

In the 1800s, the average human life was roughly 40 years with that number increasing double the original in the 21st century (Yfantopoulos 2024)— what changed? The concept of medicine has been around for much longer than we may believe, with early humans experimenting with varying plants for healing and poison,  and medicine has advanced enormously since, yet it is far from perfect. Drugs take years to develop with one major obstacle being drug delivery. Key issues include bioavailability, systemic exposure, effective penetration, and detection and eradication by virus and immune system. An up-in-coming solution for this is nanoparticles.

Nanoparticles (NPs) or more so nanotechnology focus on the manipulation of matter scaled at microscopic dimensions of 1 to 100 nanometers, ultimately providing unique physicochemical enhancements. The earliest development of nanoparticle-based drug carriers began in the 1960-1970s, beginning with lipid and polymeric-based carriers (Park 2007). Many pharmaceuticals, when given intravenously or taken orally, spread throughout the body rather than concentrating at the diseased site, with a large portion of the drug to be removed by metabolic enzymes. For severe infections, this may induce resistant strains causing the medication to be inapplicable for use. NPs address this through targeted delivery, concentrating the drug where it is needed.  

To understand the targeted delivery, the types of nanocarriers are essential. Lipid and polymeric nanocarriers behave similarly by protecting molecules from premature degradation and non-toxic biodegradation (Lu et al. 2021). Lipid carriers, such as solid lipid nanocarriers (SLNs) and nanostructured lipid carriers (NLCs), have higher biocompatibility and mimicry, while polymeric such as poly(glycolide-co-lactide) (PLGA) and chitosan, offer greater structural rigidity (Lee and Kim 2025). Either is chosen based on compositional compatibility with the target disease (i.e. TB infection within granuloma). Either can be decorated with ligands such as mannose, hyaluronic acid, or folic acid, which bind to specific receptors and trigger receptor-mediated entry into target cells (Fallatah et al. 2025).

Once in the bloodstream, nanocarriers accumulate within infected tissue through the enhanced permeability and retention (EPR) effect in which leaky blood vessels and inflamed tissue allow for the entry of macromolecules (Grimm and Scheinberg 2011). Polyethylene glycol (PEG) coatings (polymer based) hide NPs from the immune system, extending their half-life and giving them more time to accumulate within the infected tissue. Some carriers also have the ability to release their therapeutic only when triggered by specific environments, ultimately maximizing the therapeutic effects while also minimizing unnecessary exposure elsewhere. 

How NPs enter the body is highly dependent on the infected location, with common routes being intravenous, oral, and inhalation. The first FDA-approved nanodrug, Doxil, is a liposomal form of the chemotherapy drug doxorubicin given intravenously (Barenholz 2012). Inhaled carriers target lung infections such as TB by delivering the drug directly to the site rather than through the bloodstream.  Most notably, lipid carriers transported mRNA in the COVID-19 vaccines, bringing nanomedicine to billions (Wilson and Geetha 2022). Each required specific compositions of NPs carriers (polymer-lipid hybrid) for varying delivery routes, identifying the need of not only recognizing the diseased site but as well as the local biological barriers. 

Despite the promise, few nanomedicines reach the market. One analysis found that a median of only 0.7% of injected NPs reach a tumour, with most building up in the liver and spleen (Wilhelm et al. 2016). Plasma proteins can coat NPs and block target ligands and the EPR effect varies widely between patients and infections. Current research is turning toward personalized LNP therapies, cell membrane-coated particles, and AI-guided carrier design (Mitchell et al. 2020). NPs may not have solved drug delivery yet, but they are shaping how the next generation of drugs will be discovered.

References

Barenholz, Yechezkel Chezy. 2012. “Doxil® — the First FDA-Approved Nano-Drug: Lessons Learned.” Journal of Controlled Release 160 (2): 117–34. https://doi.org/10.1016/j.jconrel.2012.03.020.

Fallatah, Mohannad M., Ibrahim Alradwan, Nojoud Alfayez, et al. 2025. “Nanoparticles for Cancer Immunotherapy: Innovations and Challenges.” Pharmaceuticals 18 (8): 1086. https://doi.org/10.3390/ph18081086.

Grimm, Jan, and David A. Scheinberg. 2011. “Will Nanotechnology Influence Targeted Cancer Therapy?” Seminars in Radiation Oncology 21 (2): 80–87. https://doi.org/10.1016/j.semradonc.2010.10.003.

Lee, Ye Jin, and Moon Suk Kim. 2025. “Advances in Drug-Loaded Microspheres for Targeted, Controlled, and Sustained Drug Delivery: Potential, Applications, and Future Directions.” Biomedicine & Pharmacotherapy 189 (June): 118244. https://doi.org/10.1016/j.biopha.2025.118244.

Lu, Hongyun, Shengliang Zhang, Jinling Wang, and Qihe Chen. 2021. “A Review on Polymer and Lipid-Based Nanocarriers and Its Application to Nano-Pharmaceutical and Food-Based Systems.” Frontiers in Nutrition 8 (December). https://doi.org/10.3389/fnut.2021.783831.

Mitchell, Michael J., Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas, and Robert Langer. 2020. “Engineering Precision Nanoparticles for Drug Delivery.” Nature Reviews Drug Discovery 20 (1): 1–24. https://doi.org/10.1038/s41573-020-0090-8.

Park, Kinam. 2007. “Nanotechnology: What It Can Do for Drug Delivery.” Journal of Controlled Release 120 (1–2): 1–3. https://doi.org/10.1016/j.jconrel.2007.05.003.

Wilhelm, Stefan, Anthony J. Tavares, Qin Dai, et al. 2016. “Analysis of Nanoparticle Delivery to Tumours.” Nature Reviews Materials 1 (5): 16014. https://doi.org/10.1038/natrevmats.2016.14.

Wilson, Barnabas, and Kannoth Mukundan Geetha. 2022. “Lipid Nanoparticles in the Development of mRNA Vaccines for COVID-19.” Journal of Drug Delivery Science and Technology 74 (August): 103553. https://doi.org/10.1016/j.jddst.2022.103553.

Woo, Yeeun, Jinwook Yoon, Yoseph Seo, et al. 2025. “Structure-Centered Design of Lipid-Based Nanocarriers to Overcome Biological Barriers.” Materials Today Bio 35 (October): 102425–25. https://doi.org/10.1016/j.mtbio.2025.102425.

Yfantopoulos, John. 2024. “Life Expectancy From Prehistoric Times to the 21St Century.” Deltos 34 (52): 60–70. https://doi.org/10.12681/dj.38288.

Comments

6 Responses to “Revolutionizing Medicine: The Power of Thinking Small”

  1. Prithika Ramasamy Avatar
    Prithika Ramasamy

    Hi iSci! My blog post explores an up-and-coming form of drug delivery. It was inspired by RP2 and by the drug discovery RP coming up next term. I’ve always been interested in how therapeutics are developed and the ethics behind them, so this felt like a great topic to dig into. Enjoy!

  2. Jo Jo Sun Avatar
    Jo Jo Sun

    Hi Prithika, I really enjoyed reading your blog post! It is a very interesting topic and you did a great job explaining it. Here are some suggestions that will hopefully help you in the editing stage:

    -In P1S1, the in-text citation in between the sentence is a bit awkward, consider placing that at the end of the sentence
    -I think for P1 you could also mention other factors that changed (eg. sanitation and nutrition) that contributed to increasing life expectancy alongside with the medication advancements
    -It would be great if you could include an image of the types of nanocarriers
    -I don’t know if it is just on my end but there sometimes is an underline before the in-text citations, please double-check your formatting

    Looking forward to your final draft!
    Jojo

  3. Matteo Esposito Avatar
    Matteo Esposito

    Really interesting post! I liked how you connected nanoparticles to real-world applications like COVID-19 vaccines. One suggestion I have is regarding the line 4 paragraph 4, “PEG coatings hide NPs from the immune system.” I think briefly explaining how these coatings prevent immune recognition would make this part easier for readers to understand. Great job overall and happy editing!

  4. Anchan Zhou-Moore Avatar
    Anchan Zhou-Moore

    Hello Prithika, I loved reading about nanoparticles, really cool!!

    I have a couple of suggestions that could hopefully help with the editing process. There are a couple times throughout the blog where there appears to be an underscore before an in text citation. It appears in P1, 5, and 6. Also, maybe consider adding a figure to break up some text. Potentially showing the different types of nanocarriers as explained in P3. Overall great work! I can’t wait to see the final product!

    Happy editing!
    Anchan

  5. Stephanie Chan Avatar
    Stephanie Chan

    Hi Prithika! I loved reading your post. I really enjoyed how you used a real life example to connect to your topic. I have a few suggestions.

    P2S3: This is my personal preference but I feel like this sentence is a bit long. I think if you could split it into two sentences to improve the readability. Perhaps something like “Many drugs, whether taken orally or given intravenously, spread throughout the body rather than concentrating at the diseased site. Much of the dosage is then broken down by metabolic enzymes.”

    In addition, I think adding a figure showing a diagram of the different types of lipid and polymeric carriers would strengthen your blog post by giving your readers a visual representation of them.

    Overall, great job! I’m looking froward to the final draft.
    Stephanie

  6. Myan Nguyen Avatar
    Myan Nguyen

    Hi Prithika,

    Great blog post! I enjoyed learning about the use of nanoparticles in developing better targeted drug delivery, it is definitely an interesting avenue of research! Here are some suggestions to help during the editing process:

    – You mention many acronyms but don’t use them again (like SLNs and NLCs), consider removing them as it is not needed to abbreviate terms that will only mentioned once.

    – There are other acronyms that you can consider mentioning the full name first before abbreviating, such as TB and FDA

    – I agree with Stephanie that adding a figure showing the different types of carriers would be very helpful.

    Overall, great work! Happy editing 🙂

    Myan

Leave a Reply